SCHEMBL1721167

SCHEMBL1721167

CCOC(=O)N1CCC(c2nn(C)c3c2c2ccccc2c(=O)n3C(=O)OCC)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
TSHR P16473 4/20 0.46
GAA P10253 2/20 0.45
KMT2A Q03164 2/20 0.45
PARP1 P09874 1/20 0.45
MEN1 O00255 1/20 0.45
MAPT P10636 1/20 0.45
CHRM4 P08173 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
HTT P42858 2/20 0.43
NPSR1 Q6W5P4 1/20 0.42
HTR1A P08908 1/20 0.42
DRD2 P14416 1/20 0.42
HTR2A P28223 1/20 0.42
DRD3 P35462 1/20 0.42
HSD17B10 Q99714 6/20 0.42
KDM4E B2RXH2 5/20 0.42
NOS2 P35228 1/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1720065 0.80 PARP1 (0.71) ALDH1A1TSHRGAAKMT2APARP1
SCHEMBL12786014 0.73 ALDH1A1 (0.59) ALDH1A1TSHRGAAKMT2APARP1
SCHEMBL1720529 0.71 ALDH1A1 (0.51) ALDH1A1TSHRGAAKMT2AMEN1
SCHEMBL1720663 0.70 ALDH1A1 (0.47) ALDH1A1TSHRGAAKMT2APARP1
SCHEMBL23966556 0.67 MAPT (0.58) ALDH1A1KMT2AMEN1MAPTSMN1; SMN2
SCHEMBL10899544 0.66 L3MBTL1 (0.50) ALDH1A1TSHRGAAKMT2AMEN1
SCHEMBL10737898 0.66 ELANE (0.47) ALDH1A1TSHRSMN1; SMN2HSD17B10KDM4E
SCHEMBL23966558 0.65 RECQL (0.57) ALDH1A1MAPTSMN1; SMN2L3MBTL1NPSR1
SCHEMBL1720599 0.65 HSD17B10 (0.52) ALDH1A1TSHRGAAKMT2AMEN1
SCHEMBL31426765 0.65 CNR1 (0.50) GAAMAPTCHRM4SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1566380-B1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2012-01-11 EP disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US disclosed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof PARP1, NQO1, PARP3 ALDH1A1 169/4885TSHR 4866/4885GAA 505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.